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Summary
Background: Few data are available on the effects of age and comorbidity on treat-
ment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease 
(IBD).
Aims: To evaluate the association between age and comorbidity with safety and ef-
fectiveness outcomes of vedolizumab and ustekinumab in IBD.
Methods: IBD patients initiating vedolizumab or ustekinumab in regular care were 
enrolled prospectively. Comorbidity prevalence was assessed using the Charlson 
Comorbidity Index (CCI). Association between age and CCI, both continuously as-
sessed, with safety outcomes (any infection, hospitalisation, adverse events) during 
treatment, and effectiveness outcomes (clinical response and remission, corticos-
teroid-free remission, clinical remission combined with biochemical remission) after 
52 weeks of treatment were evaluated. Multivariable logistic regression was used to 
adjust for confounders.
Results: We included 203 vedolizumab- and 207 ustekinumab-treated IBD patients, 
mean age 42.2 (SD 16.0) and 41.6 (SD 14.4). Median treatment duration 54.0 (IQR 
19.9-104.0) and 48.4 (IQR 24.4-55.1) weeks, median follow-up time 104.0 (IQR 
103.1-104.0) and 52.0 weeks (IQR 49.3-100.4). On vedolizumab, CCI associated inde-
pendently with any infection (OR 1.387, 95% CI 1.022-1.883, P = 0.036) and hospital-
isation (OR 1.586, 95% CI 1.127-2.231, P = 0.008). On ustekinumab, CCI associated 
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1  | INTRODUC TION
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) 
and ulcerative colitis (UC), is a chronic immune-mediated disease 
predominantly affecting the gastrointestinal tract that is charac-
terised by a relapsing and remitting disease course.1 The presence 
of IBD associates with an increased risk of comorbidities, such as 
cardiovascular diseases and diabetes mellitus.2,3,4 Furthermore, the 
increase in both incidence and prevalence of IBD and the aging of 
the general population lead to an increasingly aging IBD patient pop-
ulation with a higher prevalence of comorbidities.5,6
In recent years, patient age has been focused on as a potential risk 
factor for adverse treatment outcomes in immunomodulator or biolog-
ical therapy.7-9 A number of these studies have found an increased risk 
of infections in older patients, especially those treated with biological 
agents.7 However, a patients chronological age is an imperfect marker 
of the reduced physiologic reserve capacity that predisposes patients 
to an increased risk of adverse treatment outcomes.10
The presence of comorbidities could function as a more solid pre-
dictor of therapy outcomes as compared to age itself as its presence 
increases the risk of medication interactions, reduced adherence to 
treatment and poorer response to treatment.11 In immunomodulator 
and anti-TNF-treated IBD patients, an increased risk for infections in 
patients with comorbidities has been detected.12,13 For thiopurine 
treatment, an independent association between cardiovascular risk 
factors and adverse events was observed.14
Vedolizumab, an α4β7 antibody,15,16 and ustekinumab, a human 
IgG antibody targeting the p40 subunit of IL-12 and IL-23,17 were in-
troduced for the treatment of IBD offering an alternative treatment 
option with a different mechanism of action than, for example, an-
ti-TNF therapy.18 Both vedolizumab and ustekinumab have displayed a 
favourable safety profile in the registration trials and observational co-
horts.15-17,19,20 However, in registration trials, both patients of advanced 
age and those with significant comorbidities failed to meet the strict in- 
and exclusion criteria, whereas observational cohorts did not evaluate 
patients with comorbidities. Therefore, it is currently unknown what 
the impact of the presence of comorbidities is on treatment outcomes 
of vedolizumab- and ustekinumab-treated IBD patients.
Using data from the Dutch Initiative on Crohn and Colitis (ICC) 
Registry,19,20 a nationwide prospective registry for IBD patients start-
ing novel therapies in standard care, this study aims to assess the 
impact of patient age and comorbidities on safety and effectiveness 
outcomes in vedolizumab- and ustekinumab-treated IBD patients.
2  | MATERIAL S AND METHODS
2.1 | Study design
This is a prospective multicentre cohort study using the Dutch ICC 
registry, which is a nationwide, observational registry with prospective 
and systematic follow-up of IBD patients starting IBD treatment in the 
Netherlands, as previously described in detail.19,20 Briefly, the ICC reg-
istry is used to document the usage, safety and effectiveness of ved-
olizumab and ustekinumab therapy in IBD patients. Enrolled patients 
follow a pre-defined schedule of out-patient visits and closely follow 
regular care. Visits are scheduled at baseline (initiation of therapy), and 
at weeks 12, 24, 52, 104 or until discontinuation of medication. An 
electronic case report form (eCRF) is used to collect data.
2.2 | Patients
Patients aged 16 years or older with a confirmed clinical, endo-
scopic and/or histological diagnosis of CD, UC or IBD-Unclassified 
(IBD-U) and initiating vedolizumab or ustekinumab in regular care 
were enrolled at 10 participating centres. Data were collected 
between August 2014 and June 2019. This study included only 
CD patients on ustekinumab therapy as ustekinumab has only 
recently been approved for UC patients in the Netherlands. The 
decision to start therapy was at the discretion of the treating phy-
sician and there were no exclusion criteria other than mentioned in 
the summary of product characteristics. All eligible patients in the 
participating centres were approached for participation. When 
patients changed hospital to continue treatment, the information 
of subsequent visits would be collected through contact with the 
respective patient and their new treatment facility. Patients who 
stopped going to their scheduled hospital visits or their infusions 
were recorded as discontinued at request of patient, were con-
sidered treatment failures and imputed as non-responders in the 
subsequent visits.
2.3 | Baseline characteristics
Baseline characteristics included age, gender, weight, height, disease 
duration, behaviour and location according to the Montreal classifi-
cation (maximum extent at inclusion), previous medication and prior 
independently with hospitalisation (OR 1.621, 95% CI 1.034-2.541, P = 0.035). CCI 
was not associated with effectiveness, and age was not associated with any outcomes.
Conclusions: Comorbidity - but not age - is associated with an increased risk of hos-
pitalisations on either treatment, and with any infection on vedolizumab. This un-
derlines the importance of comorbidity assessment and safety monitoring of IBD 
patients.
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intestinal resections. Disease severity was measured by the Harvey 
Bradshaw Index (HBI) for CD patients and the Simple Clinical Colitis 
Activity Index (SCCAI) for UC and IBD-U patients. The use of con-
comitant immunosuppressive medication was also registered.
The Charlson Comorbidity Index (CCI) was used to identify the 
prevalence of comorbidities prior to initiation of vedolizumab or usteki-
numab therapy. The CCI is a weighted index taking into account the 
number and severity of 16 pre-defined comorbidities and is validated 
for stratifying risk of comorbid conditions in longitudinal studies.21 For 
example, the presence of uncomplicated diabetes generates a CCI of 1 
point and the presence of a local solid tumour generates 2 points. Age 
is not included in this index. Theoretically, the CCI could range from a 
minimum of zero to a maximum of 33 points. In all included patients, 
the presence of comorbidities was assessed prior to starting therapy 
and verified using the electronical medical record.
2.4 | Outcomes
All outcomes were systematically assessed by following a pre-de-
fined schedule of out-patient visits. To determine safety outcomes, 
all enrolled patients were analysed. Safety outcomes included: 
any infection, hospitalisations, treatment-related adverse events 
and adverse events resulting in discontinuation of IBD treatment. 
Infections were classified as mild (no use of antibiotics or antiviral 
mediation necessary), moderate (oral antibiotic or antiviral medica-
tion) or severe (hospitalisation or intravenously administrated an-
tibiotics/antiviral medication). Hospitalisations included all-cause 
hospitalisations and were further specified in IBD related, infection 
or malignancy related, or other. Medication-related adverse events 
were classified as not related, possibly or probably related. Only 
adverse events that were possibly or probably related are reported 
in this study. Adverse events requiring discontinuation of therapy 
were reported separately. In addition, malignancies occurring during 
treatment and mortality were noted.
To determine effectiveness outcomes, patients with clinical dis-
ease activity at baseline (defined by HBI >4 or SCCAI >2 points) 
were analysed. Effectiveness outcomes included: clinical response, 
clinical remission, corticosteroid-free clinical remission and clinical 
remission combined with biochemical remission. Clinical response 
was defined as a reduction of at least 3 points in HBI or 3 points 
in SCCAI compared to baseline. Clinical remission was defined as 
HBI ≤4 or SCCAI ≤2 points. Biochemical remission was defined as 
a C-reactive protein (CRP) ≤5 mg/L and a faecal calprotectin (FCP) 
level ≤250 μg/g (when available). All effectiveness outcomes were 
measured at week 52.
2.5 | Statistical analysis
Data analyses were performed using ibm spss Statistics for windows, 
version 25.0. Continuous variables are presented as mean with 
standard deviation (SD) or as median with interquartile range (IQR) 
depending on the normality of the underlying distribution. Variables 
are compared using an independent T test or Mann Whitney U test. 
Categorical variables are presented as counts and percentages and 
compared by using the chi-squared test. Multivariable binary logis-
tic regression was used to assess the association between comor-
bidities and outcomes of interest. The regression analyses were 
performed as complete case analyses and the maximum number 
of missing cases per inserted variable was 1. Potential confounders 
were agreed upon beforehand and used in all multivariable binary 
logistic regression models. These variables included: age, gender, 
IBD type, disease duration and concurrent medication at baseline 
(no concurrent medication, steroid or immunomodulator use, steroid 
and immunomodulator use). In the safety analysis with the outcome 
adverse events requiring treatment discontinuation, multivariable anal-
ysis including only age and CCI was performed due to the small num-
ber of outcomes. To account for differences in treatment duration 
in the safety analyses, treatment duration was added as a variable 
in the regression model. When statistical significance was reached 
in the ‘all patients’ analysis, we performed an additional multivari-
able analysis with CCI as categorical variable (categories 0, 1, 2 or 
≥3) in the model. To assess the impact of CCI on drug survival, a 
multivariable Cox proportional hazards model was used with the 
above-mentioned confounders, using treatment duration as time 
and treatment cessation as outcome. Patients were analysed on an 
intention-to-treat basis. A two-sided P < 0.050 was considered sta-
tistically significant.
2.6 | Ethical consideration
The study was reviewed and approved by the Committee on Research 
Involving Human Subjects at the Radboudumc (Institutional Review 
Board: 4076). All patients gave their informed consent prior to inclu-
sion in the study. The study was conducted in accordance with the 
principles of the Declaration of Helsinki.
3  | RESULTS
3.1 | Baseline characteristics
In the ICC Registry, 410 cases (203 vedolizumab and 207 usteki-
numab) were enrolled and assessed on the presence of comorbidities 
using the CCI. Ninety-five patients had one or more comorbidities, 
of which 49 (51.6%) received vedolizumab treatment and 46 (48.4%) 
received ustekinumab. Sixty-three (15.4%) patients were aged 
60 years or older, 140 (34.1%) between 40 and 60 years and 206 
(50.2%) <40 years, 36 patients aged 60 years or older were treated 
with vedolizumab and 27 patients aged 60 years or older with usteki-
numab. Baseline characteristics are presented in Table 1 comparing 
patients with and without comorbidities. An additional table com-
paring baseline characteristics of vedolizumab- and ustekinumab-
treated patients is presented separately in Table S1.
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Mean age in patients with comorbidities was 50.1 years (SD 
16.1) and mean age in patients without comorbidities 39.4 years 
(SD 14.0, P < 0.001). Both groups were predominantly women: 
60.0% and 56.5% respectively (P = 0.546). In patients with co-
morbidities, 71 patients (74.7%) were diagnosed with CD and 23 
patients (24.2%) with UC. Median treatment duration and median 
follow-up time did not differ between patients with and without 
comorbidities (51.9 weeks [23.0-101.4] vs 48.9 weeks [23.5-94.3], 
P = 0.460 and 102.4 [52.0-104.0] vs 102.4 [52.0-104.0], P = 0.427 
respectively). Montreal classification did not differ between 
groups, except for age at diagnosis, which was higher in patients 
with comorbidities. Disease duration was comparable between the 
two groups (12.4 years [4.9-19.9] vs 11.0 years [5.8-18.8]). Clinical 
disease activity and medication use at baseline did not differ be-
tween patients with and without comorbidities, although patients 
with comorbidity reported less biological use in their medical his-
tory compared to patients without comorbidity.
3.2 | Baseline comorbidity prevalence
Prevalence of comorbidities at baseline is presented in Table 2. 
The most prevalent comorbidities were cardiovascular disease 
(congestive heart failure, myocardial infarction, peripheral vas-
cular disease and cerebrovascular accident [CVA] or transient 
ischemic attack [TIA]), connective tissue disease, pulmonary dis-
ease (chronic obstructive pulmonary disease [COPD] or asthma) 
and diabetes. The prevalence of comorbidities was numerically 
but not statistically significantly higher in vedolizumab-treated 
patients. However, more cardiovascular and pulmonary diseases 
were present in the vedolizumab-treated group (cardiovascular: 
20 [9.9%] vs 7 [3.4%], P = 0.031 and pulmonary: 16 [7.9%] vs 7 
[3.4%], P = 0.048).
3.3 | Age, comorbidity and safety outcomes
3.3.1 | Infections
Infections, classified as mild, moderate and severe, are presented 
in Table S2a. The most frequently observed infections were related 
to the upper respiratory tract and flu-like symptoms. In total, 4.5 
infections of any classification per 10 patient years of exposure oc-
curred during follow-up, 6.4 infections in patients with comorbidi-
ties and 3.9 in patients without comorbidities. 5.9 infections of any 
classification per 10 patient years of exposure occurred in patients 
aged ≥60 years, compared to 3.1 in patients aged between 40 and 
60 years and 5.0 in patients aged <40 years.
2.1 severe infections per 10 patient years of exposure occurred 
in patients with comorbidities and 0.6 in patients without comor-
bidities. In patients aged 60 years or older, 1.2 severe infections per 
10 patient years of exposure occurred in patients aged 60 years or 
older, 0.4 in patients aged between 40 and 60 years and 1.4 in pa-
tients younger than 40.
The CCI was not associated with the occurrence of any infec-
tion during treatment in all patients (OR 1.277, 95% CI 0.998-1.634, 
P = 0.052). However, in vedolizumab-treated patients the CCI was 
significantly associated with the occurrence of any infection during 
treatment (OR 1.387, 95% CI 1.022-1.883, P = 0.032), which was 
independent of age, gender, IBD type, disease duration, concur-
rent medication and treatment duration. No significant association 
between the CCI and any infection was observed in ustekinum-
ab-treated patients (Table 3).
Age at baseline was not associated with the occurrence of any 
infection during treatment in all patients (OR 0.984, 95% CI 0.966-
1.003, P = 0.109), or in vedolizumab- (OR 0.985, 95% CI 0.961-
1.009, P = 0.219) and ustekinumab- (OR 0.987, 95% CI 0.956-1.018, 
P = 0.397) treated patients separately (Table 3).
3.3.2 | Hospitalisations
A total of 138 hospitalisations occurred during treatment, 5.0 per 
10 patient years of exposure in patients with comorbidities and 
2.7 in patients without comorbidities. 3.4 hospitalisations per 10 
patient years of exposure occurred in patients aged ≥60 years, 2.9 
in patients aged between 40 and 60 years and 3.5 in patients aged 
younger than 40 years. The majority of hospitalisations were IBD re-
lated (78 hospitalisations, 56.5%) or infection or malignancy related 
(35 hospitalisations, 25.4%). Fourteen hospitalisations (10.1%) were 
classified as other and 15 (8.0%) as unknown. Hospitalisations are 
presented in Table S2b.
The CCI was independently associated with the occurrence of 
one or more all-cause hospitalisations during treatment in all patients 
(OR 1.450, 95% CI 1.119-1.879, P = 0.005) and in both vedolizumab- 
(OR 1.586, 95% CI 1.127-2.231, P = 0.008) and ustekinumab-treated 
patients (OR 1.623, 95% CI 1.035-2.546, P = 0.035) separately 
(Table 4). Patients using concurrent immunosuppressive medication 
at baseline were also at a higher risk of hospitalisation during both 
vedolizumab and ustekinumab treatment (steroid or immunomod-
ulator use: OR 1.928, 95% CI 1.123-3.311, P = 0.017, steroid and 
immunomodulator use: OR 3.684, 95% CI 1.650-8.229, P = 0.001). 
A CCI of 3 points or higher was significantly and independently as-
sociated with hospitalisation during treatment (OR 4.943, 95% CI 
1.778-13.738, P = 0.002) when analysing the CCI as a categorical 
variable (categories 0, 1, 2 or ≥3) in all patients. Furthermore, we 
observed a strong and independent impact of cardiovascular disease 
(comprising the CCI categories myocardial infarction, congestive 
heart failure, peripheral vascular disease and CVA/TIA) on all-cause 
hospitalisations in vedolizumab-treated patients (OR 3.954, 95% CI 
1.048-14.924, P = 0.042). Age at baseline was not associated with 
the occurrence of one or more hospitalisations during treatment in 
all patients (OR 0.986, 95% CI 0.965-1.008, P = 0.204), or in vedol-
izumab- (OR .986, 95% CI .958-1.014, P = 0.313) and ustekinumab 
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TA B L E  1   Baseline characteristics
One or more comorbidities (n = 95) No comorbidity (n = 315) P-value
Treatment, N (%)
Vedolizumab 49 (51.6) 154 (48.9) 0.646
Ustekinumab 46 (48.4) 161 (51.1)
Age (years), mean (SD) 50.1 (16.1) 39.4 (14.0) <0.001
Gender—female, N (%) 57 (60.0) 178 (56.5) 0.546
Body mass index, Mean (SD) 25.2 (5.0) 23.7 (4.5) 0.029
IBD type, N (%)
Crohn's disease 71 (74.7) 256 (81.3) 0.375
Ulcerative colitis 23 (24.2) 57 (18.1)
IBD unclassified 1 (1.1) 2 (0.6)
Disease duration (y), Median (IQR) 12.4 (4.9-19.9) 11.0 (5.8-18.8) 0.697
Treatment duration (wk), Median (IQR) 51.9 (23.0-101.4) 48.9 (23.5-94.3) 0.501
Follow-up time (wk), Median (IQR) 102.4 (52.0-104.0) 102.4 (52.0-104.0) 0.427
Montreal classification
Age at diagnosis (y), N (%)
≤16 7 (7.4) 71 (22.5) <0.001
17-40 57 (60.0) 204 (64.8)
>40 31 (32.6) 40 (12.7)
Disease location (CD)a  , N (%)
Ileum 21 (29.6) 80 (31.4) 0.845
Colon 26 (36.6) 84 (32.9)
Ileocolonic 24 (33.8) 91 (35.7)
Upper GI involvement (CD)a , N (%) 5 (7.0) 18 (7.1) 0.996
Disease behaviour (CD)a , N (%)
Inflammatory 37 (52.1) 135 (52.9) 0.348
Stricturing 22 (31.0) 65 (25.5)
Penetrating 9 (12.7) 50 (19.6)
Unknown 3 (4.2) 5 (2.0)
Peri-anal disease (CD)a , N (%) 8 (11.3) 49 (19.4) 0.117
Disease location (UC/IBD-U)a , N (%)
Proctitis 2 (8.3) 4 (6.8) 0.892
Left-sided colitis 11 (45.8) 25 (42.4)
Pancolitis 10 (41.7) 28 (47.5)
Unknown 1 (4.2) 2 (3.4)
Prior intestinal resections, N (%) 43 (45.3) 148 (47.0) 0.768
Prior anti-TNF therapy (ever use anti-TNF), N (%) 85 (89.5) 311 (98.7) <0.001
Prior VEDO therapy, N (%) 10 (21.7) 72 (44.7) 0.005
Prior USTE therapy, N (%) 1 (2.0) 6 (3.9) 0.535
Clinical disease activity, median (IQR)
HBI 8.0 (5.0-10.0) 7.0 (5.0-10.0) 0.079
SCCAI 5.0 (3.0-7.0) 6.0 (3.5-9.0) 0.519
Biochemical disease activity, median (IQR)
CRP (mg/L) 6.0 (3.0-16.0) 8.0 (2.0-21.0) 0.319
FCP (μg/g) 552.0 (197.5-1223.8) 932.5 (296.8-1999.5) 0.044
(Continues)
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(OR .986, 95% CI .951-1.021, P = 0.418) treated patients separately 
(Table 4).
Next, safety analyses for hospitalisations were performed while 
including only the IBD-related and infection or malignancy-related 
hospitalisations as an outcome. We found that in all patients (OR 
1.349, 95% CI 1.007-1.806, P = 0.045) and in ustekinumab patients 
(OR 1.625, 95% CI 1.002-2.634, P = 0.049), the CCI was associated 
with IBD- and infection- or malignancy-related hospitalisations. We 
did not find this association in vedolizumab patients separately (OR 
1.388, 95% CI 0.933-2.066, P = 0.105).
3.3.3 | Adverse events
Adverse events are listed in Table S2c and are classified as possibly 
or probably related to treatment. 3.4 adverse events per 10 patient 
years of exposure were reported in patients with comorbidities and 
2.7 in patients without comorbidities. 2.9 adverse events per 10 pa-
tient years of exposure were reported in patients aged ≥60 years, 
3.4 in patients aged 40-60 years and 2.5 in patients <40 years. 
There was no significant association among age, the CCI and oc-
currence of adverse events in all patients and in vedolizumab- or 
ustekinumab-treated patients when analysed separately (Table S3).
In total, 0.3 adverse events per 10 patient years of exposure were 
classified as a reason for treatment discontinuation, 0.8 in patients 
with comorbidities and 0.2 in patients without comorbidities (Table 
S4). In patients aged ≥60 years, 0.1 adverse event per 10 patient years 
of exposure was classified as a reason for treatment discontinuation, 
in patients aged 40-60 years 0.5 and in patients aged <40 years 0.3.
The CCI was not associated with these adverse events that led to 
treatment discontinuation (Table S5). Two patients with comorbidi-
ties were diagnosed with a malignancy and discontinued medication: 
one patient on vedolizumab aged ≥60 years had a peritonitis carcino-
matosa originating from the digestive tract and one patient aged be-
tween 40 and 60 years on ustekinumab had a peritoneal carcinoma. 
Three patients without comorbidities were diagnosed with a malig-
nancy; one died (see below) and two patients discontinued treat-
ment: one patient aged 40-60 years on vedolizumab had progression 
of a known anaplastic oligodendroglioma and one patient on usteki-
numab aged ≥60 years was diagnosed with an unknown malignancy. 
Two patients without comorbidities died during treatment, both 
aged between 40 and 60 years: one patient on vedolizumab due to a 
thrombosis in the basilar artery and one patient on ustekinumab due 
to an abdominal sepsis after colonoscopic perforation after diagno-
sis of peritoneal carcinoma.
3.4 | Age, comorbidity and effectiveness outcomes
Patients with active disease (HBI >4 or SCCAI >2) at baseline were 
included in the effectiveness analyses. The CCI was not associated 
with effectiveness outcomes (clinical remission, clinical response, 
corticosteroid-free clinical remission and combined biochemical and 
clinical remission) in all included patients. However, in ustekinumab-
treated patients, a higher age at baseline was independently associ-
ated with a mildly higher rate of combined biochemical and clinical 
remission (OR 1.043, 95% CI 1.003-1.085, P = 0.036). Results are 
presented in Tables S6a–d.
Age and the CCI were not associated with drug survival in all 
patients (age: HR 0.991, 95% CI 0.977-1.004, P = 0.985 and CCI: HR 
1.002, 95% CI 0.847-1.184, P = 0.985), or in vedolizumab- or usteki-
numab-treated patients separately (age: HR 0.996, 95% CI 979-
1.013, P = 0.617 and CCI: HR 0.899, 95% CI 0.725-1.115, P = 0.333 
and age: HR 0.977, 95% CI 0.955-1.000, P = 0.054 and CCI: HR 
1.349, 95% CI 0.998-1.823, P = 0.051).
4  | DISCUSSION
This study aimed to assess the impact of age and comorbidities on 
safety and effectiveness outcomes in vedolizumab- and usteki-
numab-treated IBD patients using data from the Dutch ICC Registry. 
In contrast to age, the presence of comorbidities was independently 
associated with impaired safety outcomes in both vedolizumab- and 
ustekinumab-treated patients. Comorbidities were independently 
associated with the occurrence of any infection during vedolizumab 
One or more comorbidities (n = 95) No comorbidity (n = 315) P-value
Concomitant medication, N (%)
No immunosuppressants 44 (46.3) 142 (45.2) 0.953
Corticosteroid or immunomodulator 42 (44.2) 139 (44.3)
Both corticosteroid and immunomodulator 9 (9.5) 33 (10.5)
Missing data: age 1 missing; BMI 134 missing; disease duration 1 missing; treatment duration 1 missing; follow-up time 1 missing; disease location 
(CD) 1 missing; upper GI involvement 1 missing; perianal disease 3 missing; HBI 10 missing; SCCAI 2 missing; CRP 87 missing; FCP 180 missing; 
concomitant medication 1 missing.
Abbreviations: anti-TNF, anti-tumor necrosis factor; CD, Crohn's disease; CRP, C-reactive protein; FCP, fecal calprotectin. ; GI, gastrointestinal; HBI, 
Harvey Bradshaw Index; IBD, inflammatory bowel disease; IBD-U, IBD-Unclassified; IQR, interquartile range; N, number; SCCAI, simple clinical colitis 
activity index; SD, standard deviation; UC, ulcerative colitis.
aMaximum extent until exclusion. 
TA B L E  1   (Continued)
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treatment, and with all-cause hospitalisation during both vedoli-
zumab and ustekinumab treatment. No association among age, co-
morbidities and impaired effectiveness outcomes was found.
Clinical trials frequently follow strict exclusion criteria regarding 
advanced age and the presence of comorbidities such as biochemic 
abnormalities, the presence of an unstable or uncontrolled medical 
disorder15 or a history of cancer.17 In our real-life cohort, 15.4% of 
the included patients were aged 60 years or older. The prevalence 
of comorbidities according to the CCI was 24.1% in vedolizumab- 
and 23.7% in ustekinumab-treated patients. Most of these patients 
would have been excluded from clinical trials. As a result, little data 
on comorbidities and their prevalence and especially relevance in 
IBD are available.11 The prevalence of comorbidities found in our 
prospective cohort is comparable to a retrospective study by Khan 
et al in which 63.759 IBD patients who initiated corticosteroids, im-
munomodulators or biologic therapy were analysed. In this study, 
25.7% of the overall cohort had one or more comorbidities according 
to the CCI.22 However, other studies using the same CCI have shown 
a wide range of comorbidity prevalence. In these studies, the preva-
lences ranged from less than one fifth to more than two thirds of the 
included patients with one or more comorbidities.12,23
In our study, we found no association between age and safety 
outcomes. This finding is comparable with a recently published me-
ta-analysis by Piovani et al which found no evidence of an increased 
risk of any infection in older IBD patients treated with biologics9 but 
in contrast to a meta-analysis published last year in older patients 
exposed to biologics.7 However, next to age, we also assessed the 
presence of comorbidities. In our study, comorbidities were inde-
pendently associated with safety outcomes in both vedolizumab- and 
ustekinumab-treated patients. In both treatment groups, an increase 
in the CCI was significantly associated with all-cause hospitalisation 
during treatment. Analysing the CCI as a categorical variable (cat-
egories 0, 1, 2 or ≥3), the presence of 3 points or higher was sig-
nificantly associated with all-cause hospitalisation during treatment. 
Furthermore, we performed safety analyses regarding hospitalisa-
tions including only IBD- and infection- or malignancy-related hos-
pitalisations as an outcome. In this analysis we found the CCI to be 
significantly associated with IBD- and infection- or malignancy-re-
lated hospitalisations in all patients and in ustekinumab patients, but 
not in vedolizumab patients. An increase in CCI was associated with 
any infection during treatment in vedolizumab (OR 1.387, 95% CI 
1.022-1.883, P = 0.036), but not in ustekinumab-treated patients 
(OR 0.998, 95% CI 0.611-1.630, P = 0.994). While earlier studies 
showed an association between comorbidities and adverse events 
for immunomodulators,14 this association was not found for vedoli-
zumab or ustekinumab in our study.
Although the impact of age and comorbidities was analysed for 
vedolizumab- and ustekinumab-treated patients separately, these 
analyses do not allow a direct comparison between both treatment 
groups for safety outcomes due to selection bias. An increase in CCI 
was associated with IBD-related and infection- or malignancy-re-
lated hospitalisations in the ustekinumab group, and with any infec-
tion during treatment in the vedolizumab group. In our study, only 
CD patients, and not UC patients, on ustekinumab were included. 
Furthermore, ustekinumab-treated patients had a higher percentage 
of previous anti-TNF therapy, or previously failed on vedolizumab 
therapy (Table S1). Besides this, since vedolizumab is considered to 
be a safe treatment option due to its supposed gut-specific mech-
anism of action, it is likely that patients who were at an increased 
infection risk were initiated on vedolizumab therapy. This hypoth-
esis is supported by the fact that vedolizumab-treated patients had 
a higher absolute number of comorbidities and a higher number of 
patients with a high CCI (a score of 3 or more). Especially a higher 




(n = 207) P-value
Charlson comorbidity index, N (%)
0 154 (75.9) 161 (77.8) 0.247
1 26 (12.8) 33 (15.9)
2 8 (3.9) 6 (2.9)
≥3 15 (7.4) 7 (3.4)
Diabetes
Uncomplicated (1) 7 (3.4) 8 (3.9)
End-organ damage (2) 2 (1.0) 0 (0.0)
Liver disease
Mild (1) 0 (0.0) 2 (1.0)
Moderate to severe (3) 4 (2.0) 2 (1.0)
Solid tumour
Localised (2) 3 (1.5) 1 (0.5)
Metastatic (6) 0 (0.0) 0 (0.0)
Leukaemia (2) 0 (0.0) 0 (0.0)
Lymphoma (2) 2 (1.0) 1 (0.5)
AIDS (6) 0 (0.0) 0 (0.0)
Chronic kidney disease (2) 8 (3.9) 5 (2.4)
Congestive heart failure (1) 6 (3.0) 1 (0.5)
Myocardial infarction (1) 9 (4.4) 3 (1.4)
Pulmonary disease (1) 16 (7.9) 7 (3.4)
Peripheral vascular  
disease (1)
1 (0.5) 1 (0.5)
CVA or TIA (1) 4 (2.0) 2 (1.0)
Dementia (1) 1 (0.5) 0 (0.0)
Hemiplegia (2) 0 (0.0) 0 (0.0)
Connective tissue disease 
(1)
11 (5.4) 21 (10.1)
Peptic ulcer (1) 2 (1.0) 4 (1.9)
Total number of 
comorbidities
76 58 0.523
Categories of CCI were compared between groups by using chi-squared 
test, total number of comorbidities by using Mann-Whitney U Test. 
Numbers next to each comorbidity represent number of points given 
according to CCI.
Abbreviations: AIDS, acquired immune deficiency syndrome; CVA, 
cerebrovascular accident; TIA, transient ischemic attack.
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number of cardiovascular diseases and pulmonary diseases were ob-
served in these patients.
The association between the presence of comorbidity and im-
paired safety outcomes found in this study could be explained by the 
fact that comorbidity is a predictor of impaired immunity and frailty 
which could lead to impaired safety outcomes.24 Furthermore, medi-
cation interactions due to polypharmacy as a consequence of comor-
bidity could influence the results. However, the route of metabolism 
of ustekinumab and the working mechanism of vedolizumab have 
not fully been characterised.25-27
No association among age, comorbidities and impaired effec-
tiveness outcomes was found in our study. In line with this ob-
servation, prior studies in IBD patients receiving other biologicals 
also did not find an association among age, comorbidities and 
impaired effectiveness outcomes.8,28 For example, Lobatón 
et al studied the impact of comorbidities in anti-TNF treated pa-
tients, and found no association between comorbidities (CCI>0) 
and efficacy outcomes.28 In our study, an independent association 
between an increasing age and a higher rate of biochemical and 
clinical remission in ustekinumab-treated patients was observed. 
This further underlines the fact that the effectiveness of biolog-
ical therapies is no less in patients of advanced age. Overall, we 
did not find a significant impact of age and CCI on drug survival, 
although in ustekinumab patients both age and CCI were border-
line significant. With an increasing age, patients tended to have a 
lower chance of therapy cessation (HR .977, 95% CI .955-1.000, 
TA B L E  3   Safety analysis—any infection
All patients OR 95% CI P-value
CCI 1.277 0.998-1.634 0.052
Age at baseline (y) 0.984 0.966-1.003 0.109
Gender (female) 0.930 0.586-1.476 0.757
Crohn's disease (ref. UC/IBDU) 0.907 0.478-1.722 0.766
Disease duration (y) 1.011 0.986-1.037 0.393
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 1.155 0.718-1.856 0.552
Steroid and immunomodulator 0.809 0.361-1.816 0.607
Treatment duration (wk) 1.014 1.007-1.020 0.000
Treatment (ustekinumab) 0.758 0.449-1.282 0.301
Vedolizumab OR 95% CI P-value
CCI 1.387 1.022-1.883 0.036
Age at baseline (y) 0.985 0.961-1.009 0.219
Gender (female) 0.746 0.397-1.401 0.362
Crohn's Disease (ref. UC/IBDU) 1.007 0.520-1.952 0.983
Disease duration (y) 0.993 0.958-1.030 0.720
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 1.067 0.550-2.070 0.849
Steroid and immunomodulator 0.683 0.251-1.857 0.455
Treatment duration (wk) 1.012 1.004-1.019 0.002
Ustekinumab OR 95% CI P-value
CCI 1.134 0.720-1.788 0.587
Age at baseline (y) 0.987 0.956-1.018 0.397
Gender (female) 1.174 0.584-2.363 0.652
Disease duration (y) 1.025 0.987-1.064 0.197
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 1.187 0.594-2.373 0.627
Steroid and immunomodulator 0.959 0.229-4.012 0.954
Treatment duration (wk) 1.017 1.005-1.028 0.005
All patients: 409 patients included in analysis of which 119 reached endpoint; VEDO: 203 patients, endpoint: 70 patients; UST: 206 patients included 
in analysis of whom 49 reached endpoint. Multivariable binary logistic regression analysis was performed and CCI was analysed as a continuous 
variable.
Abbreviations: CI, confidence interval; CCI, Charlson Comorbidity Index; IBDU, IBD-Unclassified; OR, odds ratio; UC, ulcerative colitis.
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P = 0.054) and with increasing points on the CCI patients tended 
to have a higher chance of therapy cessation (HR 1.349, 95% CI 
0.998-1.823, P = 0.051).
The results of our study have several clinical implications. First, 
although age in itself was not associated with impaired safety out-
comes, patients with comorbidities were older. Therefore, we advise 
treating gastroenterologists to be aware of this higher prevalence 
of comorbidities in older IBD patients and, when comorbidity is 
suspected, to perform adequate screening and referral as deemed 
necessary. Second, in particular a CCI of 3 points or higher and the 
presence of cardiovascular disease were associated with impaired 
safety outcomes (all-cause hospitalisation). This subanalysis identi-
fied a group of patients with an especially elevated risk for impaired 
safety outcomes which should be monitored closely. Third, concom-
itant immunosuppressive medication use at baseline was associated 
with hospitalisation during vedolizumab and ustekinumab therapy in 
our study and with infections in other studies.29 Prior studies have 
shown no significant differences in effectiveness rates when com-
paring vedolizumab or ustekinumab monotherapy to vedolizumab 
or ustekinumab therapy combined with immunosuppressive medi-
cation.19,20 Therefore, we discourage concomitant immunosuppres-
sive medication use in patients in which multiple comorbidities are 
present as well.
Our study has several strengths. This is the first study assess-
ing the impact of comorbidities next to age on therapy outcomes 
in vedolizumab- and ustekinumab-treated IBD patients. The ICC 
TA B L E  4   Safety analysis—hospitalisation
All patients OR 95% CI P-value
CCI 1.450 1.119-1.879 0.005
Age at baseline (y) 0.986 0.965-1.008 0.204
Gender (female) 1.521 0.903-2.561 0.115
Crohn's disease (ref. UC/IBDU) 2.655 1.245-5.663 0.012
Disease duration (y) 1.006 0.978-1.035 0.675
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 1.928 1.123-3.311 0.017
Steroid and immunomodulator 3.684 1.650-8.229 0.001
Treatment duration (wk) 0.999 0.992-1.006 0.857
Treatment (ustekinumab) 0.580 0.336-1.004 0.052
Vedolizumab OR 95% CI P-value
CCI 1.586 1.127-2.231 0.008
Age at baseline (y) 0.986 0.958-1.014 0.313
Gender (female) 1.558 0.759-3.200 0.227
Crohn's disease (ref. UC/IBDU) 3.468 1.523-7.897 0.003
Disease duration (y) 0.969 0.927-1.012 0.156
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 1.618 0.737-3.550 0.230
Steroid and immunomodulator 4.503 1.551-13.071 0.006
Treatment duration (wk) 0.996 0.987-1.004 0.329
Ustekinumab OR 95% CI P-value
CCI 1.623 1.035-2.546 0.035
Age at baseline (y) 0.986 0.951-1.021 0.418
Gender (female) 1.427 0.652-3.122 0.374
Disease duration (y) 1.042 0.999-1.086 0.054
Concurrent medication (ref. no concurr. medication)
Steroid or immunomodulator 2.269 1.051-4.901 0.037
Steroid and immunomodulator 1.861 0.436-7.945 0.402
Treatment duration (wk) 1.008 0.996-1.021 0.179
All patients: 409 patients included in analysis of whom 90 reached endpoint; VEDO: 203 patients, endpoint: 51 patients; UST: 206 patients included 
in analysis of whom 39 reached endpoint. Multivariable binary logistic regression analysis was performed and CCI was analysed as a continuous 
variable.
Abbreviations: CI, confidence interval; CCI, Charlson Comorbidity Index; IBDU, IBD-Unclassified; OR, odds ratio; UC, ulcerative colitis.
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Registry is a large prospective real-life cohort without restricting 
in- and exclusion criteria and a nationwide coverage. Hence, the in-
cluded patients are a representative cohort from non-academic and 
academic centres, reflecting daily IBD care. Finally, comorbidity was 
assessed systematically, using a validated comorbidity index that al-
lows external validity.
However, since this is an ongoing registry, not all patients were 
followed for the same time period. We intended to limit this by cor-
recting for follow-up duration in safety analyses. It is possible that 
results of our study are subjected to ascertainment bias: patients 
with comorbidities generally have more hospital visits or physician 
contacts, and therefore, a safety outcome, such as infection, could 
be noted more frequently in this group. However, to limit this type 
of bias, the ICC registry applies scheduled visits with automated 
reminders for strict adherence to protocol in all patients. The co-
morbidity index, the CCI, is a commonly used index to assess the 
number and severity of comorbidities but is not specifically validated 
for IBD patients. Furthermore, not all comorbidities, such as neuro-
logical conditions, are accounted for in this index. An IBD-validated 
comorbidity index is, therefore, needed.11 Finally, the number of old 
or very old patients was low in this study, which could have led to an 
underestimation of the effect of old age or CCI on treatment safety.
In conclusion, this study demonstrates that comorbidities, 
and not age, are independently associated with any infection and 
hospitalisations in vedolizumab-treated IBD patients and hospi-
talisations in ustekinumab-treated IBD patients. Effectiveness of 
both treatments was not impaired by presence comorbidities or 
a higher age. These results underline the importance of assessing 
comorbidity status instead of age prior to initiating vedolizumab 
and ustekinumab therapy, in order to discuss additional safety 
risks and need for close monitoring in IBD patients with multiple 
comorbidities.
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